2023
Years of life lost due to deaths of despair and COVID-19 in the United States in 2020: patterns of excess mortality by gender, race and ethnicity
Entrup P, Brodsky L, Trimble C, Garcia S, Mohamed N, Deaner M, Martell J, Teater J, Jordan A, Tetrault J, Hall O. Years of life lost due to deaths of despair and COVID-19 in the United States in 2020: patterns of excess mortality by gender, race and ethnicity. International Journal For Equity In Health 2023, 22: 161. PMID: 37612748, PMCID: PMC10464324, DOI: 10.1186/s12939-023-01949-9.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol-Related DisordersAmerican Indian or Alaska NativeAsianBlack or African AmericanCause of DeathCost of IllnessCOVID-19Cross-Sectional StudiesDrug OverdoseEthanolEthnicityFemaleHealth InequitiesHispanic or LatinoHumansLife ExpectancyMaleMortality, PrematureNative Hawaiian or Other Pacific IslanderRace FactorsSex FactorsSocial Determinants of HealthSuicideUnited StatesWhiteConceptsYears of lifeDeaths of despairCOVID-19Mental health workforce developmentCross-sectional studyICD-10 codesCause of deathCOVID-19 mortalityCDC WONDER databaseSubstance use treatmentHealth workforce developmentLatino personsExcess mortalityMortality burdenMore deathsDeath recordsHigh mortalityBehavioral health researchSocial determinantsGreater burdenYLLUse treatmentConclusionsThis studyPandemic onsetMortality
2022
Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment
Haque L, Fiellin D, Tate J, Esserman D, Bhattacharya D, Butt A, Crystal S, Edelman E, Gordon A, Lim J, Tetrault J, Williams E, Bryant K, Cartwright E, Rentsch C, Justice A, Re V, McGinnis K. Association Between Alcohol Use Disorder and Receipt of Direct-Acting Antiviral Hepatitis C Virus Treatment. JAMA Network Open 2022, 5: e2246604. PMID: 36515952, PMCID: PMC9856353, DOI: 10.1001/jamanetworkopen.2022.46604.Peer-Reviewed Original ResearchConceptsCurrent alcohol use disorderLow-risk drinkingAlcohol use disorderVeterans Health AdministrationHistory of AUDDAA treatmentAlcohol use categoriesAUD historyCohort studyRisk drinkingUse disordersDirect acting antiviral (DAA) treatmentAlcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaireHepatitis C virus infectionHepatitis C virus (HCV) treatmentCox proportional hazards regressionC virus infectionC virus treatmentProportional hazards regressionTenth Revision diagnosisAUDIT-C questionnaireInternational Statistical ClassificationRelated Health ProblemsAntiviral treatmentRevision diagnosis
2020
Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis.
Haque LY, Jakab S, Deng Y, Ciarleglio MM, Tetrault JM. Substance Use Disorders in Recently Hospitalized Patients With Cirrhosis. Journal Of Addiction Medicine 2020, 14: e337-e343. PMID: 32530887, PMCID: PMC9033633, DOI: 10.1097/adm.0000000000000677.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersAddiction treatmentAlcohol-related liver diseaseImpact of SUDHepatitis C infectionMedical record reviewMinority of patientsNumber of hospitalizationsRoutine clinical careAlcohol use disorderHepatology clinicC infectionCause mortalityConsecutive patientsMedian ageCommon etiologyLiver diseaseRecord reviewSignificant morbidityRetrospective studySUD careCirrhosisClinical careHospitalizationInterprofessional Substance Use Disorder Education in Health Professions Education Programs: A Scoping Review.
Muzyk A, Smothers ZPW, Andolsek KM, Bradner M, Bratberg JP, Clark SA, Collins K, Greskovic GA, Gruppen L, MacEachern M, Ramsey SE, Ruiz Veve J, Tetrault JM. Interprofessional Substance Use Disorder Education in Health Professions Education Programs: A Scoping Review. Academic Medicine 2020, 95: 470-480. PMID: 31651435, DOI: 10.1097/acm.0000000000003053.Peer-Reviewed Original ResearchConceptsHealth professions education programsMedical Education Research Study Quality InstrumentSubstance Use Disorder EducationEducation programsEducational outcomesDisorder educationHealth professions students' knowledgeStudents’ educational outcomesHealth professions educatorsMean MERSQI scoreSUD educationCurriculum designEducation studiesStudent behaviorStudents' knowledgeMERSQI scoreFuture workforceSUD courseInterprofessional collaborationEducationQuality InstrumentEducational interventionValidity evidenceAreas of improvementStudents
2019
Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial
Krishnan-Sarin S, O’Malley S, Franco N, Cavallo DA, Tetrault JM, Shi J, Gueorguieva R, Pittman B, Krystal JH. Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. Neuropsychopharmacology 2019, 45: 319-326. PMID: 31590179, PMCID: PMC6901445, DOI: 10.1038/s41386-019-0536-z.Peer-Reviewed Original ResearchConceptsAlcohol drinking behaviorFirst treatment periodTreatment periodNumber of drinksCrossover trialDrinking behaviorEfficacy of naltrexoneOpioid antagonist naltrexoneNMDA antagonist memantinePositive family historyDay treatment periodSelf-administration periodAlcohol-induced stimulationAd lib accessMemantine treatmentAntagonist naltrexoneOpioid systemFamily historyNTXPriming drinkMemantineNaltrexoneAlcohol cravingHeavy drinkersAlcohol dependenceThe Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortexA randomized trial of decision support for tobacco dependence treatment in an inpatient electronic medical record: clinical results
Bernstein SL, Weiss J, DeWitt M, Tetrault JM, Hsiao AL, Dziura J, Sussman S, Miller T, Carpenter K, O’Connor P, Toll B. A randomized trial of decision support for tobacco dependence treatment in an inpatient electronic medical record: clinical results. Implementation Science 2019, 14: 8. PMID: 30670043, PMCID: PMC6343239, DOI: 10.1186/s13012-019-0856-8.Peer-Reviewed Original ResearchConceptsPatient's primary care providerPrimary care providersTobacco treatment medicationsElectronic health recordsTobacco use disorderQuit ratesTreatment medicationsProblem listCare providersUse disordersOne-year quit ratesState tobacco quitlineTobacco quit ratesPrescription of medicationsTobacco dependence treatmentProcess of careSingle hospital systemElectronic medical recordsInpatient electronic medical recordPatient's problem listSustained quittingAdult patientsControl patientsCurrent smokingHospitalized smokersUnhealthy Alcohol Use in Primary Care-The Elephant in the Examination Room.
Edelman EJ, Tetrault JM. Unhealthy Alcohol Use in Primary Care-The Elephant in the Examination Room. JAMA Internal Medicine 2019, 179: 9-10. PMID: 30422276, DOI: 10.1001/jamainternmed.2018.6125.Peer-Reviewed Original Research
2018
“No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder
Oldfield BJ, Muñoz N, Boshnack N, Leavitt R, McGovern MP, Villanueva M, Tetrault JM, Edelman E. “No more falling through the cracks”: A qualitative study to inform measurement of integration of care of HIV and opioid use disorder. Journal Of Substance Use And Addiction Treatment 2018, 97: 28-40. PMID: 30577897, DOI: 10.1016/j.jsat.2018.11.007.Peer-Reviewed Original ResearchConceptsOpioid use disorderIntegration of HIVUse disordersClinical staffCare of HIVCommunity-based participatory research principlesBehavioral health integrationImproved patient outcomesEvidence-based treatmentsDiverse care settingsParticipatory research principlesPrimary carePatient outcomesPatient-centered policiesCare settingsHealth integrationHIVQualitative studyStages of changeClinic leadershipCare instrumentIntegrated carePatientsBehavioral healthMeasures of qualityEffects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users
Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. Journal Of Addiction Medicine 2018, 12: 227-233. PMID: 29438157, PMCID: PMC5970035, DOI: 10.1097/adm.0000000000000392.Peer-Reviewed Original ResearchConceptsLow-dose naltrexoneTobacco usersTreatment outcomesPlacebo-controlled human laboratory studySmoking cessation treatmentEffects of vareniclineCigarettes ad libitumHuman laboratory studiesSubjective drug effectsVarenicline monotherapyCessation medicationsMedication therapyCessation treatmentMedication armTobacco useVareniclineLow doseSmoking relapseSmokingDrug effectsSmoking outcomesSmoking behaviorNaltrexoneCarbon monoxide levelsHeavy drinkersPilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior
Verplaetse TL, Weinberger AH, Ashare RL, Pittman BP, Shi JM, Tetrault JM, Lavery M, McKee SA. Pilot investigation of the effect of carvedilol on stress-precipitated smoking-lapse behavior. Journal Of Psychopharmacology 2018, 32: 1003-1009. PMID: 29692206, PMCID: PMC6258014, DOI: 10.1177/0269881118767647.Peer-Reviewed Original ResearchConceptsEffects of carvedilolSmoking lapse behaviorAdrenergic antagonistsTobacco cravingSmoking outcomesPhysiologic reactivitySystolic blood pressureNumber of cigarettesNicotine-motivated behaviors× time effectSelf-administration periodEffects of α1Human laboratory modelNicotine-deprived smokersPlacebo groupBlood pressureAdrenergic antagonismMedication conditionClinical indicationsNoradrenergic systemSubsequent smokingHeart rateProperties of drugsSmokingCarvedilolAddressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder
Holt SR, Donroe JH, Cavallo DA, Tetrault JM. Addressing discordant quantitative urine buprenorphine and norbuprenorphine levels: Case examples in opioid use disorder. Drug And Alcohol Dependence 2018, 186: 171-174. PMID: 29579725, DOI: 10.1016/j.drugalcdep.2017.12.040.Peer-Reviewed Original ResearchConceptsOngoing illicit drug usePatient-provider relationshipOpioid use disorderIllicit drug useUse disordersUrine adulterationTreatment planDrug useQuantitative urine testingMethadone treatment programsSubstance use disordersNorbuprenorphine levelsUrine buprenorphineUrine testingPatientsTreatment programNonjudgmental approachUrine samplesTherapeutic allianceDiscordant levelsBuprenorphineDisordersUrineNorbuprenorphineLevels
2017
The Addiction Recovery Clinic
Holt SR, Segar N, Cavallo DA, Tetrault JM. The Addiction Recovery Clinic. Academic Medicine 2017, 92: 680-683. PMID: 28441678, DOI: 10.1097/acm.0000000000001480.Peer-Reviewed Original ResearchConceptsPatient satisfaction surveyInternal medicine residentsRecovery clinicSubstance useMedicine residentsUse disordersAddiction medicine specialistsOpioid use disorderOutpatient clinical servicesPrimary care practicesUnhealthy substance useSubstance use disordersAddiction treatment facilitiesSatisfaction surveyDirect referralNew patientsMedicine specialistsPatientsCare practicesPatient encountersConsecutive weeksBehavioral treatmentAddiction medicineClinical servicesVisit numberEffect of doxazosin on stress reactivity and the ability to resist smoking
Verplaetse TL, Weinberger AH, Oberleitner LM, Smith KM, Pittman BP, Shi JM, Tetrault JM, Lavery ME, Picciotto MR, McKee SA. Effect of doxazosin on stress reactivity and the ability to resist smoking. Journal Of Psychopharmacology 2017, 31: 830-840. PMID: 28440105, PMCID: PMC5823502, DOI: 10.1177/0269881117699603.Peer-Reviewed Original ResearchConceptsTobacco cravingCortisol levelsSubsequent ad libitum smokingEffects of doxazosinAd libitum smokingNumber of cigarettesNicotine-motivated behaviorsSmoking lapse behaviorΑ1-adrenergic antagonistNicotine-deprived smokersTitration periodPreclinical findingsSmoking cessationNoradrenergic systemTreatment strategiesDoxazosinSmoking behaviorSmokingHuman laboratoryPhysiologic reactivityPilot studyStress reactivityEffects of stressCigarettesStress imageryOnsite treatment of HCV infection with direct acting antivirals within an opioid treatment program
Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. Journal Of Substance Use And Addiction Treatment 2017, 75: 49-53. PMID: 28237054, DOI: 10.1016/j.jsat.2016.12.014.Peer-Reviewed Original ResearchConceptsDirect acting antiviralsOpioid treatment programsPercent of patientsHCV treatmentHCV infectionActing antiviralsTreatment outcomesTreatment programOral HCV treatmentSustained virologic responseHCV treatment outcomesRoutine clinical careOngoing drug useVirologic responseRetrospective studyClinical careGeneral populationPatientsDrug useTreatmentOutcomesAntiviralsInfectionPercentPWID
2016
Primary Care Physicians’ Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs
Edelman EJ, Moore BA, Calabrese SK, Berkenblit G, Cunningham C, Patel V, Phillips K, Tetrault JM, Shah M, Fiellin DA, Blackstock O. Primary Care Physicians’ Willingness to Prescribe HIV Pre-exposure Prophylaxis for People who Inject Drugs. AIDS And Behavior 2016, 21: 1025-1033. PMID: 27896552, PMCID: PMC5344709, DOI: 10.1007/s10461-016-1612-6.Peer-Reviewed Original ResearchConceptsPrimary care physiciansPre-exposure prophylaxisCare physiciansHIV pre-exposure prophylaxisHIV risk groupMore HIVClinic patientsRisk groupsGeneral internistsPWIDAcademic general internistsPractice characteristicsDisease preventionHIVPrEPProphylaxisPatientsPhysiciansCareDrugsOnline surveyInternistsHigher willingnessLower willingnessCentral roleA Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians
Blackstock OJ, Moore BA, Berkenblit GV, Calabrese SK, Cunningham CO, Fiellin DA, Patel VV, Phillips KA, Tetrault JM, Shah M, Edelman EJ. A Cross-Sectional Online Survey of HIV Pre-Exposure Prophylaxis Adoption Among Primary Care Physicians. Journal Of General Internal Medicine 2016, 32: 62-70. PMID: 27778215, PMCID: PMC5215171, DOI: 10.1007/s11606-016-3903-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCross-Sectional StudiesFemaleHealth Knowledge, Attitudes, PracticeHealth PersonnelHealth Risk BehaviorsHIV InfectionsHumansMaleMiddle AgedMultivariate AnalysisOdds RatioPractice Patterns, Physicians'Pre-Exposure ProphylaxisPrimary Health CareSurveys and QuestionnairesConceptsPrimary care physiciansHIV care experienceCare physiciansPrEP adoptionPrEP awarenessPractice characteristicsHIV pre-exposure prophylaxisCare experiencesAcademic primary care physiciansHIV-positive patientsPre-exposure prophylaxisHealth care providersResultsThe survey response rateSectional Online SurveyPCP adoptionHIV careKey ResultsThe survey response ratePercent of respondentsRisk compensationSurvey response ratePrEP knowledgePrEP useSelf-rated knowledgeMultivariable analysisClinical championsHepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection
Tetrault JM, Tate JP, Edelman EJ, Gordon AJ, Re V, Lim JK, Rimland D, Goulet J, Crystal S, Gaither JR, Gibert CL, Rodriguez-Barradas MC, Fiellin LE, Bryant K, Justice AC, Fiellin DA. Hepatic Safety of Buprenorphine in HIV-Infected and Uninfected Patients With Opioid Use Disorder: The Role of HCV-Infection. Journal Of Substance Use And Addiction Treatment 2016, 68: 62-67. PMID: 27431048, PMCID: PMC4976086, DOI: 10.1016/j.jsat.2016.06.002.Peer-Reviewed Original ResearchConceptsLiver enzyme elevationAlcohol use disorderUninfected patientsHepatotoxic medicationsHCV infectionUse disordersComposite endpointLiver injuryHIV/HCV co-infected patientsHCV co-infected patientsHIV/HCV statusPre-existing liver injuryCo-infected patientsCohort of HIVHepatitis C infectionHIV/HCVOpioid use disorderRisk of hepatotoxicityHCV statusHepatic safetyMedian ALTC infectionChart reviewEnzyme elevationHIV infectionEffect of Varenicline Combined with High‐Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings
Verplaetse TL, Pittman BP, Shi JM, Tetrault JM, Coppola S, McKee SA. Effect of Varenicline Combined with High‐Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings. Alcohol Clinical And Experimental Research 2016, 40: 1567-1576. PMID: 27246567, PMCID: PMC4930423, DOI: 10.1111/acer.13110.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcohol-Related DisordersAlcoholic IntoxicationAssociation LearningBlood PressureCravingDose-Response Relationship, DrugDouble-Blind MethodEthanolExecutive FunctionFemaleHeart RateHumansMaleMemory, Short-TermNicotinic AgonistsPsychological TestsPsychomotor PerformanceVareniclineYoung AdultConceptsPerceptual-motor functionAlcohol use disorderExecutive cognitive functionCognitive functionDose of alcoholSubjective reactivitySubjective intoxicationHigh-dose alcoholNonalcoholic control beverageAlcohol-motivated behaviorsUse disordersEffects of vareniclineAssociative learningAversive eventsLaboratory paradigmDiastolic blood pressureAlcohol cravingControl beverageMotor responsePhysiologic reactivityAlcohol-related increasesLaboratory sessionsMotor functionBlood pressurePreliminary investigationMedical Marijuana in Patients Prescribed Opioids A Cloud of Uncertainty
Becker WC, Tetrault JM. Medical Marijuana in Patients Prescribed Opioids A Cloud of Uncertainty. Mayo Clinic Proceedings 2016, 91: 830-832. PMID: 27234481, DOI: 10.1016/j.mayocp.2016.04.008.Peer-Reviewed Original Research